A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment

JoAnn Difede, Andrew A. McAleavey, Mariel Emrich, Adina Jick, Annell Ovalles, Katarzyna Wyka, Lisa Spielman, Megan Olden, Melissa Peskin, Colleen Becket-Davenport, Amy Rubenstein, Michael J. Brownstein, Eve Damiano, Debra Itzkowitz, Shi-fang Lu, Nancy J. Needell, James H. Kocsis, Janna S. Gordon-Elliott, Neal G. Simon

Open source

DOI
10.1016/j.conctc.2023.101116
Published
2023-06
Container
Contemporary Clinical Trials Communications
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.conctc.2023.101116,
  title = {A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment},
  author = {JoAnn Difede and Andrew A. McAleavey and Mariel Emrich and Adina Jick and Annell Ovalles and Katarzyna Wyka and Lisa Spielman and Megan Olden and Melissa Peskin and Colleen Becket-Davenport and Amy Rubenstein and Michael J. Brownstein and Eve Damiano and Debra Itzkowitz and Shi-fang Lu and Nancy J. Needell and James H. Kocsis and Janna S. Gordon-Elliott and Neal G. Simon},
  year = {2023},
  journal = {Contemporary Clinical Trials Communications},
  doi = {10.1016/j.conctc.2023.101116},
  url = {https://doi.org/10.1016/j.conctc.2023.101116}
}

RIS

TY  - JOUR
TI  - A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment
AU  - JoAnn Difede
AU  - Andrew A. McAleavey
AU  - Mariel Emrich
AU  - Adina Jick
AU  - Annell Ovalles
AU  - Katarzyna Wyka
AU  - Lisa Spielman
AU  - Megan Olden
AU  - Melissa Peskin
AU  - Colleen Becket-Davenport
AU  - Amy Rubenstein
AU  - Michael J. Brownstein
AU  - Eve Damiano
AU  - Debra Itzkowitz
AU  - Shi-fang Lu
AU  - Nancy J. Needell
AU  - James H. Kocsis
AU  - Janna S. Gordon-Elliott
AU  - Neal G. Simon
PY  - 2023
JO  - Contemporary Clinical Trials Communications
DO  - 10.1016/j.conctc.2023.101116
UR  - https://doi.org/10.1016/j.conctc.2023.101116
ER  - 

APA

Difede, J., McAleavey, A. A., Emrich, M., Jick, A., Ovalles, A., Wyka, K., Spielman, L., Olden, M., Peskin, M., Becket-Davenport, C., Rubenstein, A., Brownstein, M. J., Damiano, E., Itzkowitz, D., Lu, S., Needell, N. J., Kocsis, J. H., Gordon-Elliott, J. S., & Simon, N. G. (2023). A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment. Contemporary Clinical Trials Communications. https://doi.org/10.1016/j.conctc.2023.101116

Source records